5-α reductase inhibitors, Androgen antagonists, BCG, BCG therapy, BCG-unresponsive disease, Bladder neoplasms, Bladder-sparing therapy, Bladder-sparing trimodality, Chemoradiotherapy, Clinical pathways, Clinical staging, Collaborative care, Cystectomy, Early recurrence patterns, EORTC, ERBB2, ERCC2, Gene expression analysis, Guidelines, Hematuria, Immune checkpoint, Immunoregulation, Intravesical therapy, Laparoscopic radical cystectomy, Meta-analysis, MIBC, Molecular subtypes, Neoadjuvant chemotherapy, Neoplasm recurrence, NIBC, Nuclear matrix protein 22, Oncologic outcomes, Open radical cystectomy, Optical coherence, PD-L1, PET, PLND, POUT trial, Prevention & control, Quality of life, Radical cystectomy, Radio-chemotherapy, Randomized controlled trial, RARC, RAZOR Trial, Recurrence, Robotic, Robotic prostatectomy, Robotic radical cystectomy, Robotic surgery, Surgical video, Systematic review, Tomography, Transitional cell, Transitional cell carcinoma, Tregs, Urinary bladder neoplasms, Urinary diversion, Urological surgery, Urothelial cancer